Department of Psychology, University of Alberta, Edmonton, Alberta, Canada.
Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, T6G 2E9, Canada.
Transl Stroke Res. 2020 Dec;11(6):1203-1213. doi: 10.1007/s12975-020-00824-x. Epub 2020 Jun 5.
One major aim of preclinical intracerebral hemorrhage (ICH) research is to develop and test potential neuroprotectants. Published guidelines for experimental design and reporting stress the importance of clearly and completely reporting results and methodological details to ensure reproducibility and maximize information availability. The current review has two objectives: first, to characterize current ICH neuroprotection research and, second, to analyze aspects of translational design in preclinical ICH studies. Translational design is the adoption and reporting of experimental design characteristics that are thought to be clinically relevant and critical to reproducibility in animal studies (e.g., conducting and reporting experiments according to the STAIR and ARRIVE guidelines, respectively). Given that ICH has no current neuroprotective treatments and an ongoing reproducibility crisis in preclinical research, translational design should be considered by investigators. We conducted a systematic review of ICH research from 2015 to 2019 using the PubMed database. Our search returned 281 published manuscripts studying putative neuroprotectants in animal models. Contemporary ICH research predominantly uses young, healthy male rodents. The collagenase model is the most commonly used. Reporting of group sizes, blinding, and randomization are almost unanimous, but group size calculations, mortality and exclusion criteria, and animal model characteristics are infrequently reported. Overall, current ICH neuroprotection research somewhat aligns with experimental design and reporting guidelines. However, there are areas for improvement. Because failure to consider translational design is associated with inflation of effect sizes (and possibly hindered reproducibility), we suggest that researchers, editors, and publishers collaboratively consider enhanced adherence to published guidelines.
临床前脑出血 (ICH) 研究的主要目标之一是开发和测试潜在的神经保护剂。已发布的实验设计和报告指南强调了明确和完整地报告结果和方法学细节的重要性，以确保可重复性并最大限度地提供信息。本综述有两个目的：首先，描述当前的 ICH 神经保护研究；其次，分析临床前 ICH 研究中转化设计的各个方面。转化设计是指采用和报告被认为与临床相关且对动物研究的可重复性至关重要的实验设计特征（例如，分别根据 STAIR 和 ARRIVE 指南进行和报告实验）。鉴于目前尚无针对 ICH 的神经保护治疗方法，且临床前研究中存在持续的可重复性危机，因此研究者应考虑采用转化设计。我们使用 PubMed 数据库对 2015 年至 2019 年的 ICH 研究进行了系统回顾。我们的搜索返回了 281 篇研究动物模型中潜在神经保护剂的已发表论文。当代 ICH 研究主要使用年轻、健康的雄性啮齿动物。胶原酶模型是最常用的。报告组大小、盲法和随机化几乎是一致的，但组大小计算、死亡率和排除标准以及动物模型特征的报告则很少。总体而言，当前的 ICH 神经保护研究在一定程度上与实验设计和报告指南保持一致。但是，仍有一些改进的空间。由于未能考虑转化设计与效应大小的膨胀（可能阻碍可重复性）有关，因此我们建议研究人员、编辑和出版商共同考虑加强对已发布指南的遵守。
